This study was designed to investigate the effect of administrating a selective aromatase inhibitor, letrozole, on the parameters of the rat's sperm and testicular histomorphology. A total of 40 male Wistar rats with an age of about 5 months old and an average weight of 190±10 g were divided randomly into 4 groups (n=10 each) and treated for 6 weeks. The first group (C) was given normal saline only as a control group. The second (T1), third (T2), and fourth (T3) groups received doses of 0.5, 1, and 1.5 mg/animal letrozole, respectively. At the end of the experiment (42 days), all animals were euthanized and the samples were obtained for more evolutions. The results of this study showed a significant increase in sperms quality (P-value≤0.05) while indicating a significant decrease in sperm abnormality in the T1 group, compared to the C group. Moreover, there was a significant difference represented by an increase in sperm quality, and a significant difference represented by a decrease in sperms abnormality in the T2 group, compared to the C group. On the other hand, there was a significant difference represented by an increase in sperm quality, and a significant difference represented by a decrease in sperm abnormality in the T3 group, compared to the T2 group. Normal somniferous tubules with high spermatoscopy counts were shown in histologic sections in the control group, primary and secondary spermatocytes with spermatozoa. In the T1 group, there was adequate spermatogenesis with a thick basement membrane. In the T2 group, there was normal testicular tissue with a significant increase in spermatogenic activity and number. In the T3 group, there was no significant atrophy or other pathology. The results of the current study suggested that letrozole improved spermatogenesis while causing no visible pathological alterations in testis tissue. |
- Hermo L, Pelletier RM, Cyr DG, Smith CE. Surfing the wave, cycle, life history, and genes/proteins expressed by testicular germ cells. Part 1: background to spermatogenesis, spermatogonia, and spermatocytes. Microsc Res Tech. 2010;73(4):241-78.
- Autiero M, Sansone G, Abrescia P. Relative ratios of lactoferrin, albumin, and acid phosphatase seminal levels as sperm quality markers in fertile and infertile men. J Androl. 1991;12(3):191-200.
- Rodríguez‐Martínez H, Kvist U, Ernerudh J, Sanz L, Calvete JJ. Seminal plasma proteins: what role do they play? Am J Reprod Immunol. 2011;66:11-22.
- Lønning PE, Geisler Jr, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22):5126-37.
- Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol. 2003;86(3-5):219-24.
- Geisler Jr, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20(3):751-7.
- Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol. 2009;5(10):559-68.
- Haynes B, Dowsett M, Miller W, Dixon J, Bhatnagar A. The pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003;87(1):35-45.
- Comhaire FH, Huysse S, Hinting A, Vermeulen L, Schoonjans F. OPINION: Objective semen analysis: has the target been reached? Hum Reprod. 1992;7(2):237-41.
- Van der Ven K, Montag M, Peschka B, Leygraaf J, Schwanitz G, Haidl G, et al. Combined cytogenetic and Y chromosome microdeletion screening in males undergoing intracytoplasmic sperm injection. Mol Hum Reprod. 1997;3(8):699-704.
- Graham J, Kunze E, Hammerstedt RH. Analysis of sperm cell viability, acrosomal integrity, and mitochondrial function using flow cytometry. Biol Reprod. 1990;43(1):55-64.
- Bearden HJ, Fuquay JW. Applied animal reproduction: Prentice-Hall, Inc.; 1997.
- Bancroft J, Layton C. The hematoxylin and eosin. Bancroft’s Theory and Practice of Histological Techniques, Expert Consult: Online and Print, 2012. Elsevier: Amsterdam, Netherlands.
- Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl. 2013;15(6):806.
- Shuling L, Kuei MLS, Saffari SE, Jiayun Z, Yeun TT, Leng JPW, et al. Do men with normal testosterone–oestradiol ratios benefit from letrozole for the treatment of male infertility? Reprod Biomed Online. 2019;38(1):39-45.
- Cavallini G, Beretta G, Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH. Asian J Androl. 2011;13(6):895.
- Zhao D, Pan L, Zhang F, Pan F, Ma J, Zhang X, et al. Successful use of aromatase inhibitor letrozole in NOA with an elevated FSH level: a case report. Andrologia. 2014;46(4):456-7.
- Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48-51.
- Ring JD, Lwin AA, Köhler TS. Current medical management of endocrine-related male infertility. Asian J Androl. 2016;18(3):357.
- Alves MG, Rato L, Carvalho RA, Moreira PI, Socorro S, Oliveira PF. Hormonal control of Sertoli cell metabolism regulates spermatogenesis. Cell Mol Life Sci. 2013;70(5):777-93.
- Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev. 2010;36(3):249-61.
- Kondarewicz A, Kolasa A, Zawiślak B, Baranowska-Bosiacka I, Marchlewicz M, Wenda-Różewicka L, et al. Testis morphology in rats chronically treated with letrozole, an aromatase inhibitor. Folia Histochem Cytobiol. 2011;49(4):677-84.
- Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril. 2012;98(6):1359-62.
- Ribeiro MA, Gameiro L, Scarano WR, Briton-Jones C, Kapoor A, Rosa MB, et al. Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. JBRA Assist Reprod. 2016;20(2):82-8.
- Uzun B, Atli O, Perk B, Burukoglu D, Ilgin S. Evaluation of the reproductive toxicity of naproxen sodium and meloxicam in male rats. Hum Exp Toxicol. 2015;34(4):415-29.
- Shoshany O, Abhyankar N, Mufarreh N, Daniel G, Niederberger C. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017;107(3):589-94.
- Turkistani A, Marsh S. Pharmacogenomics of third-generation aromatase inhibitors. Expert Opin Pharmacother. 2012;13(9):1299-307.
|